With a FDA fast track designation, the development of paxalisib and radiotherapy for brain metastases will be expedited.1 This new designation follows a prior fast track designation for paxalisib monotherapy in glioblastoma. Developer of paxalisib, Kazia Therapeutics, will continue to ...
The FDA has granted a fast track designation to paxalisib (formerly GDC-0084) for the treatment of patients with glioblastoma, according to an announcement from Kazia Therapeutics Limited, the developer of the drug.1 The indication is specifically for the treatment of patients with newly diagnosed...
In September 2018, Novocure (St Helier, Jersey) and Zai Lab (Shanghai, China) announced astrategic collaboration and license agreement for Novocure’s Tumor Treating Fields (TTF)medical device, marketed as Optune®. Optune was previously approved by FDA for glioblastoma in 2011. The transaction...